3 completed, 1 withdrawn. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
Follow NBI 77860: new trials by email Literature Review of NBI 77860 trials Research Report on NBI 77860
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia NBI-77860 - Congenital Adrenal Hyperplasia | Phase 1 | Withdrawn | Neurocrine Biosciences | 2015-02-01 | 2015-06-11 | |
| A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers GSK561679 tablet or solution - Healthy Subjects | Phase 1 | Completed | GlaxoSmithKline | 12 | 2007-10-01 | 2010-10-19 |
| A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder GSK561679 tablet, GW876008 tablet, alprazolam - Social Phobia | Phase 1 | Completed | GlaxoSmithKline | 35 | 2007-03-27 | 2017-08-04 |
| To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones. metyrapone, alprazolam, placebo - Depressive Disorder and Anxiety Disorders | Phase 1 | Completed | GlaxoSmithKline | 20 | 2006-10-06 | 2017-09-11 |
Anxiety Disorders (2) · Adrenal Gland Diseases (1) · Adrenal Hyperplasia, Congenital (1) · Adrenocortical Hyperfunction (1) · Adrenogenital Syndrome (1) · Congenital Abnormalities (1) · Congenital adrenal hyperplasia due to 21 hydroxylase deficiency (1) · Depression (1) · Depressive Disorder (1) · Disorders of Sex Development (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1) · Gonadal Disorders (1) · Hyperplasia (1) · Metabolic Diseases (1)
GlaxoSmithKline (3) · Neurocrine Biosciences (1)
United States (2) · Spain (1) · United Kingdom (1)